Principles of Vaccine Development

  • Constantin A. Bona
Part of the Infectious Disease book series (ID)


Two hundred years ago, Jenner devised the first vaccine able to prevent variola. This vaccine was based on the observation that subsequent to injection of a boy with cowpox, he was protected against two successive inoculations with smallpox virus. After 200 years, global administration of vaccinia has led to almost total eradication of the smallpox virus from the earth. There is no other example in medicine of a new drug or biologic substance leading to eradication of the causative agent and extinction of disease. Vaccinations against other bacteria or viruses prevents the death of millions of people yearly. However, currently vaccines do not cover the entire spectrum of diseases. There is a long list of microbes, among which are HIV and malaria, affecting millions of individuals, for which we do not yet have vaccines. This is why the development of new vaccines is a permanent aim of medical research. This interest grew because scientists have understood that vaccines can be used not only for prevention of infectious diseases but also for therapy, leading to the concept of therapeutic vaccines.


Foreign Gene Vaccine Development Subunit Vaccine Japanese Encephalitis Therapeutic Vaccine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Revillard JP (ed). Cytokine series. Int Rev Immunol 1998; 17: 1–53.Google Scholar
  2. 2.
    Braciale TL, Braciale VL. Antigen presentation: structural theme variation. Immunol Today 1992; 12: 124–129.CrossRefGoogle Scholar
  3. 3.
    Moody DB, Reinhold BB, Guy MR, et al. Structural requirements for glycolipid recognition by CD1b-restricted T-cells. Science 1997; 278: 283–286.PubMedCrossRefGoogle Scholar
  4. 4.
    Institute of Medicine. Vaccine Supply and Innovation. Washington: National Academy Press, 1985.Google Scholar
  5. 5.
    Enders JF, Weller TH, Robbins FC. Cultivation of the Lansing strain of poliomyelitis virus in culture of various human embryonic tissues. Science 1949; 109: 85–87.PubMedCrossRefGoogle Scholar
  6. 6.
    Jerne NK. Towards a network theory of the immune system. Ann Inst Pasteur Immunol 1974; 125C: 373–389.Google Scholar
  7. 7.
    Fields B, Goldbaum FA, Ysern X, Poljak RJ, and Mariuzza RA. Molecular basis of antigen mimicry by an anti-idiotype. Nature 1995; 374: 739–742.PubMedCrossRefGoogle Scholar
  8. 8.
    Bona CA. Idiotype vaccines: forgotten but not gone. Nat Med 1998; 4: 668–669.PubMedCrossRefGoogle Scholar
  9. 9.
    Bona CA. Internal image concept revisited. PSEBM 1996; 213: 32–42.Google Scholar
  10. 10.
    Tartaglia J, Percus ME, Taylor J, et al. NYVAC: a highly attenuated strain of vaccinia virus. Virology 1992; 188: 217–232.PubMedCrossRefGoogle Scholar
  11. 11.
    Taylor J, Weinberg W, Kaawaoka Y, Webster R, Paoletti E. (1988) Protective immunity against avian influenza induced by fowlpox recombinant virus. Vaccine 1988; 6: 497–503.CrossRefGoogle Scholar
  12. 12.
    Moss B. Vaccinia virus vectors. In: Elis RW (ed). Vaccines: New Approaches to Immunological Problems. Boston, Butterworth-Heineman, pp. 345–357.Google Scholar
  13. 13.
    Natuk AR, Davis PK, Chanda MD, et al. Adenovirus vectored vaccines. In: Brown F (ed). Recombinant Vectors in Vaccine Development. Dev Biol Stand 1994; 82: 71–78Google Scholar
  14. 14.
    Curtis R, Kelly SM, Tinge SM, et al. Recombinant Salmonella vactors in vaccine development. In: Brown F (ed). Recombinant Vectors in Vaccine Development. Dev Biol Stand 1994; 82: 23–33Google Scholar
  15. 15.
    Giquel B. Towards new mycobacterial vaccines. In: Brown F. (ed). Recombinant Vectors in Vaccine Development. Dev Biol Stand 1994; 82: 171–178.Google Scholar
  16. 16.
    Sirard J-C, Fayolle C, Chastellier C, Mock M, Leclerc C, Berche P. Intracytoplasmic delivery of liseriolysine O by a vaccinal strain of Bacillus anthracis induces CD8-mediated protection. J Immunol 1997; 159: 4453–4443.Google Scholar
  17. 17.
    Wolff JA, Ludtke JJ, Acsadi G, Williams P, Jani A. Long-time persistence of plasmid DNA and foreign gene expression in mouse cells. Hum Mol Genet 1992; 1: 363–369.PubMedCrossRefGoogle Scholar
  18. 18.
    Chattergoon MA, Robinson TM, Boyer LD, Weiner DB. (1998) Specific immune induction following DNA-based immunization through in vivo transfection and activation of macrophages/antigen presenting cells, J Immunol 1998; 160: 5705–5718.Google Scholar
  19. 19.
    Casares S, Inaba K, Brumeanu T-D, Steinaman RM, Bona C. Antigen presentation by dendritic cells after immunization with DNA encoding a major histocompatibility complex class II-restricted viral epitope. J Exp Med 1997; 186: 1481–1486.PubMedCrossRefGoogle Scholar
  20. 20.
    Bona CA, Casares S, Brumeanu T-D. Towards development of T-cell vaccines. Immunol Today 1998; 19: 126–133.PubMedGoogle Scholar
  21. 21.
    Isobe H, Moran T, Li S, et al. Presentation by a major histocompatibility class I molecule of nucleoprotein peptide expressed in two different genes of an influenza virus transfectant. J Exp Med 1995; 181: 202–213.CrossRefGoogle Scholar
  22. 22.
    Hahn CS, Hahn YS, Braciale TJ, Rice CM. Infectious Sindbis virus transient expression vector for studying antigen processing and presentation. Proc Natl Acad Sci USA 1992; 89: 2679–2683.PubMedCrossRefGoogle Scholar
  23. 23.
    Leclerc C (ed). Immunogenicity of foreign epitopes expressed in chimeric molecules. Int Rev Immunol 1994; 11: 103–178.Google Scholar
  24. 24.
    Russman H, Shams H, Poblete F, Fu Y, Galan JE, Donis RO. Delivery of epitopes by the Salmonella type III secretion systen for vaccine development. Science 1998; 281: 565–567CrossRefGoogle Scholar
  25. 25.
    Bona CA, Bot A, Brumeanu T-D Immunogenicity of viral epitopes expressed on genetically and enzymatically engineered immunoglobulins. Chem Immunol 1997; 65: 179–206.PubMedCrossRefGoogle Scholar
  26. 26.
    Casares S, Bot A, Brumeanu T-D, Bona C. Foreign peptides expressed in engineered chimeric molecules. Biotech Gen Eng Rev 1998; 15: 159–198.Google Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2002

Authors and Affiliations

  • Constantin A. Bona

There are no affiliations available

Personalised recommendations